Semaglutide for weight loss at NovaGenix
Semaglutide for weight loss at NovaGenix in Jupiter, Florida. In June 2021, the US food and drug administration approved Semaglutide injections 2.4 mg once weekly for the management of Obesity. This is the first time since 2014 that the FDA has approved a weight loss medication for chronic weight management in adults with obesity or overweight with at least one weight related condition like high blood pressure type two diabetes or high cholesterol. to be used in conjunction with a reduced calorie diet and increased exercise, this under the skin injection is indicated for patients with a BMI of 27 or greater with at least one weight related element, or a BMI of 30 or greater. approximately 70% of adult Americans are obese or overweight. This is a serious health risk and is associated with some of the leading causes of death in the United States with heart, disease, diabetes, and stroke, all linked to being obese, as well as several types of cancer. not to...